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 C3 glomerulopathy: what ’ s in 
a name ? 
 Vivette D.  D ’ Agati 1 and  Andrew S.  Bomback 2 
 Whereas early classifications of membranoproliferative glomerulo-
nephritis (MPGN) were based on morphologic features, the modern 
approach is directed at immunofluorescence findings. Glomerular 
deposits of C3 alone, without immunoglobulin, are the hallmark of 
alternative complement pathway dysregulation through inherited or 
acquired defects. These immunoglobulin-negative forms are referred 
to as C3 glomerulopathy, which encompasses both dense deposit 
disease and C3 glomerulonephritis. Distinguishing C3 glomerulopathy 
from immunoglobulin-mediated MPGN is opening the way to better 
diagnostic, prognostic, and treatment algorithms. 
 Kidney International (2012)  82, 379 – 381.  doi: 10.1038/ki.2012.80 
 Among glomerular diseases, none has 
undergone greater conceptual metamor-
phosis over the past fi ve years than mem-
branoproliferative glomerulonephritis 
(MPGN). In the 1970s, before there was 
knowledge of pathogenesis, MPGN was 
categorized on the basis of histologic and 
ultrastructural fi ndings. 1 – 3 Th e membran-
oproliferative pattern of glomerular injury 
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is defi ned as mesangial interposition and 
duplication of glomerular basement mem-
branes, typically associated with periph-
eral capillary wall immune deposits. Over 
the next two decades, many secondary 
forms with clear etiologic associations 
(such as related to cryoglobulinemia, dys-
proteinemia, autoimmune disease, and 
infections) were diff erentiated from the 
primary idiopathic form. But the patho-
logic classification of primary MPGN 
remained problematic because it was 
based largely on the ultrastructural 
appearance and location of deposits, 
devoid of pathogenetic context. 
 Subendothelial and mesangial deposits 
predominated in type I MPGN, where the 
membranoproliferative pattern was typi-
cally well developed. 1 Highly electron-
dense intramembranous and mesangial 
deposits were the hallmark of type II, also 
known as dense deposit disease (DDD). 2 
In type III, deposits could be subendo-
thelial and subepithelial (Burkholder 
subtype) or produce complex intramem-
branous, subendothelial, and subepithelial 
formations with fraying of the lamina 
densa (Strife and Anders subtype). 3 Even 
within the same biopsy or a given glomer-
ulus, pathologists may observe overlap-
ping features between these subtypes, 
defying easy classifi cation. While hypo-
complementemia was a well-recognized 
clinical feature of all these entities, with 
the exception of C3 nephritic factor, 
causation was largely unknown. 
 Over the next two decades, increasing 
attention was paid to the composition of 
the deposits detected by immunofl uores-
cence. Type I was typically characterized 
by deposits of immunoglobulin as well as 
complement components; type II was 
distinguished by deposits of C3 only; 
the type III Burkholder variant typically 
had deposits of immunoglobulin and 
complement; whereas the type III Strife 
and Anders variant could manifest C3 
either alone or in combination with 
immunoglobulins. As long as the patho-
genesis of these forms remained obscure, 
the classifi cation was cumbersome to use 
and perplexing to clinicians and patholo-
gists alike. 
 In the past decade, our understanding 
of the role of complement in the patho-
genesis of MPGN has illuminated the fi eld 
and led to a paradigm shift  in classifi ca-
tion ( Figure 1 ). First, the observation that 
a number of patients with intramembra-
nous dense deposits lack an MPGN pat-
tern altogether caused the designation 
MPGN II to be discarded in favor of DDD. 
Second, pathologists began emphasizing 
in their reports the presence of isolated 
deposits of C3 in examples of MPGN type 
I and type III. A major breakthrough was 
the discovery of genetic mutations or 
defi ciencies in complement-regulatory 
proteins in patients with isolated C3 
deposits. 4,5 Th ereaft er,  ‘ C3 glomerulopa-
thy ’ assumed center stage as a newly rec-
ognized subgroup encompassing DDD 
and those examples of type I and type III 
(now termed  ‘ C3 glomerulonephritis ’ ; 
C3GN) in which immunofl uorescence 
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reveals isolated deposits of C3, underscor-
ing the pathogenetic importance of 
dysregulation of the alternative comple-
ment pathway. Th us, the modern approach 
to classifi cation distinguishes those forms 
of MPGN with deposits of C3 only 
(known as C3 glomerulopathy and includ-
ing both DDD and C3GN) from MPGN 
with deposits of immunoglobulin and 
complement. 6 
 The reports from Servais  et al. 7 and 
Sethi  et al. 8 in this issue of  Kidney Interna-
tional highlight the strengths and weak-
nesses of the term  ‘ C3 glomerulopathy. ’ As 
validation of the classifi cation, defective 
control of the alternative complement 
pathway was detectable in 71 % of patients 
in the French cohort 7 (which included 
cases of C3GN, DDD, and MPGN type I) 
and 100 % of those in the American 
cohort 8 (which included cases of C3GN 
only). Th is defect can be due to mutations 
in complement proteins (such as C3, fac-
tor B, factor H, and factor I) or due 
to acquired autoantibodies that either 
stabilize the C3 convertase of the alterna-
tive pathway (e.g., C3 nephritic factors) or 
target the inhibitory complement factors 
(e.g., factor H autoantibodies). These 
abnormalities promote excessive activa-
tion of the alternative complement path-
way in the fl uid phase, with deposition of 
complement debris, including breakdown 
products of C3b and components of the 
terminal complement cascade, in the 
glomerular capillary wall. A reclassifi ca-
tion of MPGN into immunoglobulin-
mediated disease (prompting a work-up 
for infectious, autoimmune, or dyspro-
teinemia-associated etiologies) vs. com-
plement-mediated disease (prompting a 
work-up of the alternative pathway) 
should lead to better diagnostic and treat-
ment algorithms and, ideally, improved 
outcomes in these diseases. For example, 
9 of the 12 patients with C3GN in the 
American cohort were initially misclassi-
fied as having MPGN type I ( n  =  4), 
MPGN type III ( n  =  1), and postinfectious 
glomerulonephritis ( n  =  4). Th e demon-
stration by Sethi  et al. 8 that the proteomic 
profi le of C3GN by mass spectrometry 
is similar to that of DDD (with predo m-
inance of C3 and distal complement path-
way components) further supports the 
emerging view that the presence of C3 
alone is the major hallmark of alternative 
complement pathway dysregulation in C3 
glomerulopathy, independent of histo-
logic and ultrastructural features. 
 However, the pitfall of lumping diseases 
into a single descriptor or category is an 
implied assumption of homogeneity. 
As compared with atypical hemolytic ure-
mic syndrome, which is also strongly 
associated with dysregulated alternative 
complement pathway activity, C3 glomer-
ulopathy manifests a much broader 
spectrum of clinical presentation, histopa-
thology, genetic abnormalities, comple-
ment activity, and prognosis. Servais  et al. , 
looking only at the adult patients in their 
cohort, found worse 10 – year renal sur-
vival in patients with DDD than in 
patients with MPGN type I and C3GN; 7 
Sethi  et al. , in their smaller cohort, also 
report worse outcomes in DDD than in 
C3GN and suggest that C3GN may be a 
less aggressive entity. 8 One possible expla-
nation is the much higher rate of C3 
nephritic factor (C3NeF) positivity in 
DDD (86.4 % in the French cohort, in 
accordance with the approximately 80 % 
rate described in other cohorts) 9 than in 
C3GN (45.3 % in the French cohort and 
50 % in the American cohort). 7,8 Yet even 
this discrepancy is open to question, as 
Servais  et al. report a fl uctuation of the 
C3NeF activity in one-third of their 
patients during follow-up and a normal 
range of serum C3 levels in approximately 
40 % of C3NeF-positive patients, suggest-
ing that the C3NeF-stabilized C3 conver-
tase may be subject to regulation by other 
factors. 7 The authors hypothesize that 
complement-regulatory membrane cofac-
tor protein (MCP) variants may explain 
this heterogeneity of disease in C3 glomer-
ulopathy. 7 However, they are not able to 
show a functional role of their proposed 
at-risk MCP haplotype, and the  P -values 
reported for the selected single-nucleotide 
polymorphisms in the MCP gene are 
not robust enough to denote signifi cance, 
particularly without replication in an 
independent cohort. 7 
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 Figure 1  |  The evolving classification of membranoproliferative glomerulonephritis (MPGN). 
Until recently, the classification of primary MPGN into types I, II, and III was based primarily on 
histologic features (light microscopy) and the ultrastructural location and electron density of the 
deposits (electron microscopy). With our increased understanding of the role of complement in 
the pathogenesis of these conditions, the immunofluorescence findings now play a crucial role in 
categorizing MPGN as immunoglobulin-mediated vs. non-immunoglobulin-mediated disease; the 
latter grouping, which is distinguished by isolated C3 staining on immunofluorescence, has been 
termed  ‘ C3 glomerulopathy. ’ C3 glomerulopathy encompasses C3 glomerulonephritis (C3GN) and 
dense deposit disease (DDD). GBM, glomerular basement membrane; IgG, immunoglobulin G; 
IgM, immunoglobulin M. 
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 One of the most intriguing fi ndings to 
emerge from the French cohort is the 
identifi cation of alternative complement 
pathway dysregulation in more than half 
of the 48 patients with MPGN type I. 7 In 
fact, a C3NeF was identifi ed as frequently 
in MPGN type I as in C3GN. Th e termi-
nology  ‘ C3 glomerulopathy ’ is intended 
for immunoglobulin-negative diseases, 
to highlight the underlying alternative 
pathway dysregulation as opposed to acti-
vation of the classical pathway by anti-
gen – antibody immune complexes. How, 
then, should we classify the MPGN type I 
patients described here with genetic 
abnormalities in factor H ( n  =  5) or factor 
I ( n  =  3) or with positive C3NeF activity 
( n  =  18)? One possible explanation is that 
these patients were previously misclassi-
fi ed as MPGN type I, akin to some patients 
in the American C3GN cohort, and that 
the immunoglobulin staining was trace 
and inconsequential; the lack of central 
review of all biopsies in this study, as the 
authors themselves acknowledge, is there-
fore a major limitation. 7 Small amounts 
of immunoglobulin may become trapped 
in areas of sclerosis or accumulate in 
podocyte protein resorption droplets, 
confounding immunofl uorescence inter-
pretation. However, if we are to accept that 
these cases truly have immunoglobulin 
deposits alongside serologic evidence of 
alternative pathway dysregulation, should 
we now consider these as yet another sub-
type of C3 glomerulopathy? Th ese fi nd-
ings suggest more commonality between 
MPGN type I and C3 glomerulopathies 
than previously recognized and raise the 
question of whether patients with dys-
regulated alternative complement path-
way may not also develop disease-causing 
immune deposits containing immu-
noglobulin and complement in the course 
of antigen-driven immune responses. 
Such observations are consistent with 
the predisposition to immune complex-
mediated lupus nephritis in MRL-lpr mice 
with genetic deletion of complement fac-
tor H 10 and the increased susceptibility to 
IgA nephropathy in people with muta-
tions in the complement factor H locus on 
human chromosome 1q32. 11 C3NeF has 
also been identifi ed in some patients with 
postinfectious glomerulonephritis. 12 
Because patients with complement-
regulatory disorders are not protected 
from development of other immune-
mediated glomerulonephritides, future 
studies will be needed to explore the 
potential contribution of alternative path-
way complement dysregulation beyond 
C3 glomerulopathy. 
 Screening tests of alternative comple-
ment pathway activity may help clear up 
some of this confusion and provide much-
needed physiologic information supporting 
the diagnosis of C3 glomerulopathy. Sethi 
 et al. used three diff erent screening tests of 
the alternative pathway in their cohort of 
C3GN: a hemolytic assay, an alternative 
pathway functional assay, and levels of 
serum membrane attack complex. 8 In such 
a small cohort, in which most patients 
showed remarkable stability of disease 
despite varied treatment regimens, it is 
impossible to discern whether these mark-
ers of alternative pathway activity are linked 
to outcomes. Such testing would likely have 
been far more informative in the larger 
French cohort but was not performed. 7 
Instead, levels of C3 and C4 were used as 
baseline markers of complement activity, 
which by themselves are substandard in 
these complex diseases; not surprisingly, 
neither low C3 (  <  600  mg / l) nor very low 
C3 (  <  200  mg / l) levels were predictive of 
renal outcomes. 7 Wider access to the types 
of genetic and complement testing 
described in both studies should allow 
more etiology-specifi c diagnosis. 
 Another provocative fi nding is the iden-
tification of both C3NeF and a genetic 
defect in the complement pathway in a 
proportion of patients in the French 
cohort: among 24 patients with an identi-
fi ed mutation in a complement gene, 13 
also had detectable C3NeF. 7 Why is there 
coexistence of inherited and acquired 
abnormalities of the alternative comple-
ment pathway in such cases? Th ese num-
bers are diffi  cult to ascribe to coincidence 
and raise the question of whether increased 
activity of the alternative complement 
pathway on a genetic basis might promote 
autoimmune phenomena by unbridled 
activation (and perhaps conformational 
change) of the C3 convertase. Th ese fi nd-
ings suggest a two-hit disease model in 
some people. Larger cohorts are needed to 
evaluate the prevalence of this phenome-
non and the implications for evidence-
based treatment. 
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